Digital transformation consultancy Daemon announces new collaboration with UK-based healthcare company Tachmed  to enhance the speed and efficiency of bringing innovative healthcare products to the market faster. By leveraging AI to identify clinical uses and antibodies for testing, the collaboration enables Tachmed to streamline its workflows, saving as much as 50% of time that would’ve previously been spent conducting this in-depth research without support.

To accelerate clinical and use-case identification and reduce delays in developing Tachmed’s extensive assay library, Tachmed collaborated with Daemon to identify the most impactful opportunities for AI integration. Through stakeholder engagement, two-way education, upskilling initiatives and hands-on workshops, Daemon worked closely with scientists to understand key challenges in clinical use-case identification. This foundational work helped shape AI adoption, minimising delays in developing Tachmed’s extensive assay (test) library and ensuring scientists could focus on high-value research.

Innovation with AI, the Daemon way

Tachmed’s success relies on rapid discovery and evaluation of potential clinical use cases and diagnostic reagents, such as antibodies, for assay development. Previously, scientists manually sifted through scientific literature and vendor data, a process that was time-consuming, costly and prone to bottlenecks.

Daemon identified a three-step approach to using AI to eliminate these hurdles:

1. Using AI to extract the right information: Using Anthropic’s Claude’s Sonnet 3.5, available through Amazon Bedrock, the AI model extracts insights from PubMed and vendor websites. The AI also extracts antibody data.
2. Organising information for ease of use: Once the AI has extracted the key data, again powered by Anthropic’s Claude on AWS Bedrock, it organises it with two steps. First, it identifies key details, biomarkers, test types, and clinical significance. Then it synthesises the extracted data to deliver targeted, actionable, and organised insights, enabling scientists to make informed decisions without sifting through vast amounts of research or spreadsheets. This approach helps researchers efficiently identify biomarkers and clinical opportunities, accelerating assay development, saving time, and supporting faster, data-driven decision-making.
3. A scalable system for the future: Built on AWS’s managed services, the system is designed to scale with Tachmed’s growing needs, ensuring smooth performance and efficient data processing, even as the volume of information increases. AWS’ scalable infrastructure supports long-term growth while maintaining seamless operation.

To ensure rapid and effective adoption of AI solutions, Daemon also educated scientists, developers, and non-technical stakeholders on AI’s capabilities, helping to build a long-term, scalable vision. Additionally, Daemon designed and implemented a tailored user interface with an iterative approach, incorporating user feedback and testing.

Damien Duff, Principal Consultant, Machine Learning at Daemon comments, “We are committed to helping organisations harness AI to drive meaningful change. This project exemplifies how AI can improve efficiency and unlock new opportunities for innovation. By automating critical processes and enabling faster decision-making, we’re empowering scientists to focus on the breakthroughs that matter.

“Our work with Tachmed demonstrates that AI and innovation create significant opportunities to accelerate the development of healthcare products.”

Delivering measurable impact

The collaboration between Daemon and Tachmed hasrated significant real-world impact, empowering innovation as Tachmed’s team now has access to AI-driven tools to quickly discover clinical use cases and antibody candidates, driving their mission to create transformative healthcare solutions. It has also accelerated development, with the tool saving scientists up to a week on every two-week literature review and up to a week per clinical project, thereby speeding up research and reducing time-to-market for new healthcare products. Additionally, what started as a proof of concept is now in active use and ready to scale,architecture set to automate data scraping and handle larger datasets; future developments will extend AI capabilities to support data analysis and testing processes. already demonst with AI-driven

Paul Christie, CEO, Tachmed comments, “Daemon’s expertise and collaboration has been instrumental in helping us build tools that align with our mission to transform healthcare data and diagnostics. The AI-powered system the team developed is already saving us time, delivering valuable insights, and enabling us to innovate faster.

“It is the first step of using AI to revolutionise assay development and moving downstream to frontline remote, predictive, and automated user applications. This partnership is a game-changer.”